Hi Eaglenebula
Not sure I can provide any particular insight on this.
However, I would point out that in the potential pipeline shown in the presentation, glaucoma and LHON are listed as two examples of blinding eye diseases that might be treatable with PYC-001.
This suggests to me that these two indications haven’t been firmly decided; nor does it necessarily rule out acute ischemic optic neuropathy or other “blinding eye diseases where its mechanism of improving cellular bioenergetics holds potential for disease correction”.
Were the PYC-001 asset to be licensed out, I guess it would be the licensee’s call as to which indications would be pursued.
Ann: Commencement of RP11 Multiple Dose Trial, page-35
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 19.5¢ | $456.8K | 2.282M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 347837 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 103041 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |